A 19-year-old male presents with severe nodulocystic acne affecting the face, chest, and back for the past 8 months. Examination reveals large, painful, deep nodules and cysts with evidence of post-inflammatory hyperpigmentation and early ice-pick scarring. Previous trials of oral doxycycline 100 mg twice daily for 3 months combined with topical adapalene and benzoyl peroxide have failed to achieve adequate control. The clinical picture marked **D** in the diagram represents the indication for which of the following therapeutic agents?

Explanation

## Why Isotretinoin 0.5–1 mg/kg/day to cumulative dose 120–150 mg/kg is right Severe nodulocystic acne (marked **D**) is the classic and most important indication for isotretinoin (13-cis-retinoic acid). This is the ONLY agent that targets all four cardinal pathogenic factors of acne vulgaris: follicular hyperkeratinization, sebum production, *Cutibacterium acnes* colonization, and inflammation. Isotretinoin induces durable remission in 60–80% of patients and is the only agent capable of preventing permanent scarring in severe disease. The cumulative dose of 120–150 mg/kg over 4–6 months is the evidence-based standard (Bolognia Dermatology 5e, Ch 36; AAD Guidelines 2024). Given this patient's failure of conventional oral antibiotic therapy, truncal involvement, and early scarring, isotretinoin is mandatory. ## Why each distractor is wrong - **Oral minocycline 100 mg daily for 6 months**: Oral antibiotics (including minocycline) are reserved for moderate acne and must be limited to 3 months maximum to prevent resistance. They do not address all pathogenic factors and are inadequate for nodulocystic disease. Extended use beyond 3 months increases resistance risk. - **Spironolactone 50–200 mg/day with combined oral contraceptive**: Hormonal therapy (spironolactone + OCPs) is appropriate for moderate acne in adult women with androgen-driven disease (PCOS, hirsutism). This 19-year-old male patient has severe nodulocystic acne, which requires isotretinoin regardless of sex; hormonal therapy alone is insufficient. - **Intralesional triamcinolone acetonide 10 mg/mL into each nodule**: Intralesional corticosteroids are adjunctive procedures used to reduce inflammation in individual inflamed cysts and nodules, but they are NOT primary therapy for severe nodulocystic acne. They do not address the underlying pathogenic mechanisms and cannot induce remission. **High-Yield:** Severe nodulocystic acne = isotretinoin; it is the only agent that targets all four pathogenic factors and is the only treatment capable of inducing durable remission and preventing permanent scarring. [cite: Bolognia Dermatology 5e Ch 36; AAD Guidelines 2024]